Avkare Incorporated is recalling 88,718 bottles of various strengths of Valsartan and Hydrochlorothiazide combination tablets, used to treat high blood pressure. The recall was initiated because a cancer-causing impurity was detected in the active pharmaceutical ingredient (API) used to make the medication. This affects 90-count prescription bottles sold nationwide between 2017 and 2018.
The drug contains a carcinogen impurity that exceeds safety standards, which may increase the risk of cancer in patients who consume the medication over a long period. No specific injuries or adverse events have been reported to date, but the deviation from manufacturing safety standards poses a medium-term health risk.
Healthcare provider consultation and pharmacy return
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES ยท Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.